Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Power Law in COVID-19 Cases in China

Behzod B. Ahundjanov, View ORCID ProfileSherzod B. Akhundjanov, Botir B. Okhunjanov
doi: https://doi.org/10.1101/2020.07.25.20161984
Behzod B. Ahundjanov
†Department of Economics, University of Illionois, Chicago, Illionois
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sherzod B. Akhundjanov
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Sherzod B. Akhundjanov
  • For correspondence: sherzod.akhundjanov@usu.edu
Botir B. Okhunjanov
§School of Economic Sciences and Department of Mathematics and Statistics, Washington State University, Pullman, Washington
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Data/Code
  • Preview PDF
Loading

ABSTRACT

The novel coronavirus (COVID-19) was first identified in China in December 2019. Within a short period of time, the infectious disease has spread far and wide. This study focuses on the distribution of COVID-19 confirmed cases in China—the original epicenter of the outbreak. We show that the upper tail of COVID-19 cases in Chinese cities is well described by a power law distribution, with exponent around one in the early phases of the outbreak (when the number of cases was growing rapidly) and less than one thereafter. This finding is significant because it implies that (i) COVID-19 cases in China is heavy-tailed and disperse; (ii) a few cities account for a disproportionate share of COVID-19 cases; and (iii) the distribution generally has no finite mean or variance. We find that a proportionate random growth model predicated by Gibrat’s law offers a plausible explanation for the emergence of a power law in the distribution of COVID-19 cases in Chinese cities in the early phases of the outbreak.

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

No external funding is received to complete this project.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

The research project does not require IRB review.

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Footnotes

  • * We thank an anonymous reviewer for useful comments and suggestions that have significantly improved the analysis presented in the study. We also thank Wai Yan Siu for research assistance. Part of the work was completed while Behzod Ahundjanov was at Bucknell University, Lewisburg, Pennsylvania, USA. This work was supported by the UAES at Utah State University.

  • The revised version of the manuscript addresses the following points: (i) clarifies a generative mechanism of power law observed in COVID-19 cases in China; (ii) provides further support for some estimation and testing choices made in the paper; (iii) provides additional robustness checks.

Data Availability

The data used in this research project is publicly available. We provide online links to the data in the project.

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Back to top
PreviousNext
Posted October 22, 2021.
Download PDF
Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Power Law in COVID-19 Cases in China
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Power Law in COVID-19 Cases in China
Behzod B. Ahundjanov, Sherzod B. Akhundjanov, Botir B. Okhunjanov
medRxiv 2020.07.25.20161984; doi: https://doi.org/10.1101/2020.07.25.20161984
Reddit logo Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools
Power Law in COVID-19 Cases in China
Behzod B. Ahundjanov, Sherzod B. Akhundjanov, Botir B. Okhunjanov
medRxiv 2020.07.25.20161984; doi: https://doi.org/10.1101/2020.07.25.20161984

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Infectious Diseases (except HIV/AIDS)
Subject Areas
All Articles
  • Addiction Medicine (228)
  • Allergy and Immunology (504)
  • Anesthesia (110)
  • Cardiovascular Medicine (1240)
  • Dentistry and Oral Medicine (206)
  • Dermatology (147)
  • Emergency Medicine (282)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (531)
  • Epidemiology (10023)
  • Forensic Medicine (5)
  • Gastroenterology (499)
  • Genetic and Genomic Medicine (2453)
  • Geriatric Medicine (238)
  • Health Economics (479)
  • Health Informatics (1643)
  • Health Policy (753)
  • Health Systems and Quality Improvement (636)
  • Hematology (248)
  • HIV/AIDS (533)
  • Infectious Diseases (except HIV/AIDS) (11864)
  • Intensive Care and Critical Care Medicine (626)
  • Medical Education (252)
  • Medical Ethics (75)
  • Nephrology (268)
  • Neurology (2281)
  • Nursing (139)
  • Nutrition (352)
  • Obstetrics and Gynecology (454)
  • Occupational and Environmental Health (537)
  • Oncology (1245)
  • Ophthalmology (377)
  • Orthopedics (134)
  • Otolaryngology (226)
  • Pain Medicine (158)
  • Palliative Medicine (50)
  • Pathology (324)
  • Pediatrics (730)
  • Pharmacology and Therapeutics (313)
  • Primary Care Research (282)
  • Psychiatry and Clinical Psychology (2280)
  • Public and Global Health (4834)
  • Radiology and Imaging (837)
  • Rehabilitation Medicine and Physical Therapy (492)
  • Respiratory Medicine (651)
  • Rheumatology (285)
  • Sexual and Reproductive Health (238)
  • Sports Medicine (227)
  • Surgery (267)
  • Toxicology (44)
  • Transplantation (125)
  • Urology (99)